Inogen (NASDAQ:INGN) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen downgraded shares of Inogen (NASDAQ:INGN) from a hold rating to a sell rating in a research report released on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inogen in a research report on Tuesday, November 3rd. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy”.

Inogen Trading Up 1.2%

Inogen stock traded up $0.07 during mid-day trading on Friday, reaching $5.69. The company had a trading volume of 238,117 shares, compared to its average volume of 298,697. The business has a fifty day simple moving average of $6.00 and a 200 day simple moving average of $6.22. The company has a market cap of $147.94 million, a P/E ratio of -4.34 and a beta of 1.51. Inogen has a fifty-two week low of $5.05 and a fifty-two week high of $7.67.

Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Thursday, November 5th. The medical technology company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). Inogen had a negative net margin of 10.46% and a negative return on equity of 19.29%. The firm had revenue of $77.19 million during the quarter, compared to the consensus estimate of $92.25 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Integrated Wealth Concepts LLC lifted its stake in Inogen by 18.3% in the second quarter. Integrated Wealth Concepts LLC now owns 16,728 shares of the medical technology company’s stock valued at $108,000 after buying an additional 2,585 shares during the period. Steward Partners Investment Advisory LLC boosted its holdings in shares of Inogen by 1.8% during the 3rd quarter. Steward Partners Investment Advisory LLC now owns 205,181 shares of the medical technology company’s stock worth $1,081,000 after buying an additional 3,650 shares in the last quarter. Moore Capital Management LP grew its position in shares of Inogen by 3.3% during the 2nd quarter. Moore Capital Management LP now owns 289,128 shares of the medical technology company’s stock worth $1,865,000 after buying an additional 9,229 shares during the period. Royce & Associates LP acquired a new stake in shares of Inogen during the 3rd quarter worth approximately $77,000. Finally, IMC Chicago LLC acquired a new stake in shares of Inogen during the 2nd quarter worth approximately $95,000. 89.94% of the stock is owned by institutional investors and hedge funds.

About Inogen

Inogen, Inc. is a medical technology company focused on respiratory care. It develops, manufactures and markets oxygen concentrators and related products for people who require supplemental oxygen, including those with chronic respiratory conditions. Its products include the Inogen One line of portable oxygen concentrators, stationary oxygen concentrators and accessories. The company sells through direct-to-consumer channels and healthcare providers. Founded in 2001 and headquartered in Goleta, California, Inogen serves customers in the United States and international markets.